Repligen Comprehensive Income 2010-2024 | RGEN

Repligen comprehensive income for the quarter ending June 30, 2024 was $-0.044B, a 18.97% increase year-over-year.

  • Repligen comprehensive income for 2023 was $-0.037B, a 8.83% increase from 2022.
  • Repligen comprehensive income for 2022 was $-0.034B, a 103.68% increase from 2021.
  • Repligen comprehensive income for 2021 was $-0.017B, a 909.88% decline from 2020.

Repligen Comprehensive Income 2010-2024 | RGEN

  • Repligen comprehensive income for 2023 was $-0.037B, a 8.83% increase from 2022.
  • Repligen comprehensive income for 2022 was $-0.034B, a 103.68% increase from 2021.
  • Repligen comprehensive income for 2021 was $-0.017B, a 909.88% decline from 2020.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$178.9B
Regeneron Pharmaceuticals (REGN)$125.5B
Vertex Pharmaceuticals (VRTX)$122.4B
Gilead Sciences (GILD)$104.4B
Bristol Myers Squibb (BMY)$100.8B
CSL (CSLLY)$96.8B
GSK (GSK)$87.9B
Alnylam Pharmaceuticals (ALNY)$35.1B
Argenex SE (ARGX)$31.6B
Biogen (BIIB)$28.8B
BioNTech SE (BNTX)$27.5B
Moderna (MRNA)$26.9B
Illumina (ILMN)$20.9B
BeiGene (BGNE)$19.2B
Genmab (GMAB)$17.3B
BioMarin Pharmaceutical (BMRN)$13.5B
Vaxcyte (PCVX)$13B
Exact Sciences (EXAS)$12.8B
Incyte (INCY)$12.6B
Insmed (INSM)$12.5B
Bio-Techne Corp (TECH)$12.1B
Sarepta Therapeutics (SRPT)$11.9B
QIAGEN (QGEN)$10.4B
Bio-Rad Laboratories (BIO.B)$9.1B
Legend Biotech (LEGN)$9.1B
Roivant Sciences (ROIV)$8.9B
Ascendis Pharma (ASND)$8.7B
Halozyme Therapeutics (HALO)$7.9B
Intra-Cellular Therapies (ITCI)$7.9B
Exelixis (EXEL)$7.7B